Table 2. Markers of angiogenesis in patients treated with dual VEGF/VEGFR inhibition.
| Median level baseline (n = 13)a | Median level week 4 (n = 13)a | Median level week 6 (n = 9)a | P valueb baseline vs week 4 | P valueb baseline vs week 6 | P valueb week 4 vs week 6 | |
|---|---|---|---|---|---|---|
| CEC (cells/mL) | 6.5 | 17.75c | 6.12d | 0.03 | 0.85 | 0.64 |
| VEGF (pg/mL) | 360.67 | 217.19 | 167.66 | 0.07 | 0.03 | 0.004 |
| VEGFR1 (pg/mL) | 109.32 | 149.33 | 117.35 | 1.0 | 0.30 | 0.50 |
| VEGFR2 (pg/mL) | 1856.1 | 1264 | 1393.1 | 0.0002 | 0.004 | 0.03 |
| VEGFR3 (ng/mL) | 45.04 | 15.38 | 23.66 | 0.0002 | 0.004 | 0.004 |
| Endoglin (ng/mL) | 3.69 | 3.23 | 3.34 | 0.01 | 0.004 | 0.82 |
| TIE-2 (ng/mL) | 20.77 | 15.48 | 17.42 | 0.0002 | 0.004 | 0.03 |
| VCAM-1 (ng/mL) | 576.6 | 932.18 | 932.18 | 0.006 | 0.04 | 0.73 |
| Angiopoeitin-2 (pg/mL) | 2841.4 | 1537.2 | 1843.8 | 0.0002 | 0.004 | 0.04 |
| MMP-9 (ng/mL) | 609.3 | 312.8 | 363.6 | 0.01 | 0.03 | 0.25 |
| CXCL-10 (pg/mL) | 124.2 | 347.41 | 154.51 | 0.01 | 0.20 | 0.04 |
| Prokineticin-1 (ng/mL) | 0.615 | 0.646 | 0.54 | 0.22 | 1.0 | 0.57 |
| Prokineticin-2 (pg/mL) | 0.35 | 3.95 | 0.83 | 0.01 | 0.11 | 0.43 |
| S100A9 (ng/mL) | 3.26 | 2.55 | 2.8 | 0.64 | 0.10 | 0.73 |
a Unless otherwise noted; bWilcoxon signed rank test; cn = 11; dn = 10.